tiprankstipranks
Trending News
More News >
Auxly Cannabis Group Inc (TSE:XLY)
TSX:XLY

Auxly Cannabis Group (XLY) AI Stock Analysis

Compare
239 Followers

Top Page

TS

Auxly Cannabis Group

(TSX:XLY)

Rating:70Outperform
Price Target:
C$0.00
▼(-100.00%Downside)
Auxly Cannabis Group's overall stock score reflects strong technical and valuation indicators, underpinned by positive corporate events that enhance financial stability. These strengths are offset by ongoing net losses and potential overbought technical conditions, highlighting the need for continued focus on profitability and careful monitoring of market dynamics.

Auxly Cannabis Group (XLY) vs. iShares MSCI Canada ETF (EWC)

Auxly Cannabis Group Business Overview & Revenue Model

Company DescriptionAuxly Cannabis Group Inc. operates as a consumer-packaged goods company in the cannabis products market in Canada. The company focuses on developing, manufacturing, and distributing cannabis products for wellness and recreational consumers. It offers cannabis products under various forms, including vape catridges, dried flower, concentrates, chocolates, soft chews, oil drops, capsules, topicals, and hard candy under the brands KOLAB PROJECT, Dosecann, BACK FORTY, and Foray. The company was formerly known as Cannabis Wheaton Income Corp. and changed its name to Auxly Cannabis Group Inc. in June 2018. Auxly Cannabis Group Inc. was incorporated in 1987 and is based in Toronto, Canada.
How the Company Makes MoneyAuxly Cannabis Group generates revenue primarily through the sale of its branded cannabis products. The company's revenue model is centered around producing and distributing a diverse portfolio of cannabis products to licensed retailers and directly to consumers in jurisdictions where cannabis is legal. Key revenue streams include sales from dried cannabis flower, cannabis oil, and derivative products like edibles and beverages. Auxly further enhances its earnings through strategic partnerships and supply agreements with other cannabis producers and retailers, as well as its proprietary product development initiatives. These partnerships allow Auxly to expand its market reach and distribution capabilities, contributing significantly to its revenue.

Auxly Cannabis Group Financial Statement Overview

Summary
Auxly Cannabis Group is showing improvements with revenue growth and stronger cash flow positions. Despite these advancements, the company faces ongoing net losses, impacting overall profitability. Improvements in equity position and free cash flow indicate better financial management, but challenges in achieving consistent profitability persist.
Income Statement
55
Neutral
Auxly Cannabis Group has shown a positive revenue growth trend, with a recent increase from $101 million in 2023 to $122 million in 2024. However, despite improved gross profit margins, the company is still experiencing net losses, which affects the net profit margin negatively. The EBITDA margin has turned positive, indicating some operational improvements, but the absence of EBIT margin due to zero EBIT is a concern.
Balance Sheet
60
Neutral
The company has improved its equity position, with shareholder equity increasing significantly from 2023 to 2024. The debt-to-equity ratio has improved as well, indicating better leverage management. However, the equity ratio shows room for improvement, reflecting moderate financial stability amidst high total liabilities.
Cash Flow
65
Positive
Auxly Cannabis Group has exhibited strong free cash flow growth, with free cash flow growing from $6.61 million in 2023 to $14.02 million in 2024. The operating cash flow to net income ratio is positive, showing that the company is generating cash from operations despite net losses. The improvement in free cash flow to net income ratio reflects better cash flow management.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue122.33M101.08M94.47M83.83M50.80M
Gross Profit59.93M21.28M17.92M19.29M11.14M
EBITDA24.38M-10.82M-93.40M-13.64M-57.18M
Net Income-16.35M-44.51M-130.29M-45.91M-87.43M
Balance Sheet
Total Assets261.53M261.90M331.82M450.42M378.96M
Cash, Cash Equivalents and Short-Term Investments18.50M15.75M14.78M14.89M21.50M
Total Debt68.47M159.04M193.59M190.10M124.68M
Total Liabilities145.87M210.86M246.13M242.31M187.43M
Stockholders Equity115.66M51.05M90.41M212.52M195.94M
Cash Flow
Free Cash Flow14.02M6.61M-11.67M-50.01M-53.86M
Operating Cash Flow16.78M8.21M-2.48M-49.63M-33.13M
Investing Cash Flow-445.00K-1.56M1.18M17.33M-14.53M
Financing Cash Flow-13.59M-5.68M1.18M26.40M24.74M

Auxly Cannabis Group Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.10
Price Trends
50DMA
0.08
Positive
100DMA
0.08
Positive
200DMA
0.06
Positive
Market Momentum
MACD
<0.01
Negative
RSI
66.06
Neutral
STOCH
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:XLY, the sentiment is Positive. The current price of 0.1 is above the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.08, and above the 200-day MA of 0.06, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 66.06 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:XLY.

Auxly Cannabis Group Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
TSXLY
70
Outperform
$112.05M5.6518.60%26.78%
51
Neutral
$7.41B0.36-61.88%2.34%16.99%1.69%
OGOGI
$179.69M19.854.76%
$22.83M-16.22%
$27.48M3.1020.78%
TSHLS
56
Neutral
C$151.16M-23.05%-3.73%32.70%
$18.46M29.616.18%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:XLY
Auxly Cannabis Group
0.10
0.07
216.67%
OGI
OrganiGram Holdings
1.35
-0.19
-12.34%
MEDIF
MediPharm Labs
0.05
>-0.01
-16.67%
DBCCF
Decibel Cannabis Company
0.05
0.01
25.00%
TSE:HLS
HLS Therapeutics Inc
4.79
1.44
42.99%
MILFF
1CM Inc
0.30
-0.13
-30.23%

Auxly Cannabis Group Corporate Events

Private Placements and FinancingBusiness Operations and Strategy
Auxly Cannabis Group Strengthens Financial Position with Key Agreements
Positive
Jun 19, 2025

Auxly Cannabis Group Inc. has announced two significant agreements aimed at strengthening its financial position. The company has entered into a non-binding agreement to amend its existing credit facility with the Bank of Montreal, which will enhance liquidity and provide flexibility for growth initiatives. Additionally, Auxly has reached an exchange agreement with Imperial Brands to settle over $21 million of debt through equity instruments, thereby improving its capital structure and financial stability.

Shareholder Meetings
Auxly Cannabis Group Schedules Annual General Meeting for June 2025
Neutral
Jun 2, 2025

Auxly Cannabis Group Inc. announced its Annual General Meeting of Shareholders will be held on June 30, 2025, in Toronto. Due to limited seating, shareholders must pre-register to attend in person, and an audio teleconference will be available for real-time listening, though voting must be done in advance.

Business Operations and StrategyFinancial Disclosures
Auxly Cannabis Group Reports Strong Q1 2025 Results with Significant Revenue Growth
Positive
May 15, 2025

Auxly Cannabis Group Inc. reported a strong financial performance for the first quarter of 2025, with a 29% increase in net revenues to $32.7 million and a 232% rise in adjusted EBITDA. The company maintained its position as a top player in the Canadian cannabis market, with its Back Forty brand achieving the number one spot in Canada. Auxly’s strategic focus on innovation and operational efficiency has resulted in significant growth, reinforcing its market leadership and setting a solid foundation for future expansion.

The most recent analyst rating on (IMAX) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on IMAX stock, see the IMAX Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 27, 2025